An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
- 薬:adebrelimab + SHR-A2009
- 薬:adebrelimab + SHR-A2009
- 薬:adebrelimab + SHR-A2009
- 薬:paclitaxel or pemetrexed combined with carboplatin +adebrelimab
- 薬:adebrelimab
- 薬:adebeliizumab + SHR-A2009
- 薬:adebeliizumab + SHR-A2009
- 薬:adebeliizumab + platinum-containing double chemotherapy
- 薬:almonertinib combined with SHR-A2009
- 薬:almonertinib combined with SHR-A2009
- 薬:almonertinib
- 薬:SHR-A2009 combined with almonertinib
- 薬:almonertinib monotherapy
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Yijing Chen
- 電話番号:0518-82342973
- メール:yijing.chen.yc510@hengrui.com
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- Guangdong Provincial People's Hospital
-
主任研究者:
- Yilong Wu
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
- The ECOG score was 0 or 1.
- Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
- Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
- Participants with active, known or suspected autoimmune diseases.
- Other malignant tumors within 5 years before screening.
- Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
- Participants with severe cardiovascular and cerebrovascular diseases.
- There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
- Arterial and venous thrombosis events occurred within 3 months before the first administration.
- HIV test positive.
- Participants with active hepatitis B or C.
1.Evidence of active tuberculosis infection within 1 year before the first administration.
12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:group A1-1adebrelimab + SHR-A2009
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
アクティブコンパレータ:group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab
|
paclitaxel or pemetrexed combined with carboplatin +adebrelimab |
|
実験的:group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
実験的:group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
アクティブコンパレータ:group A2-3 adebrelimab
|
adebrelimab |
|
実験的:group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
実験的:group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
アクティブコンパレータ:group A3-3 adebeliizumab + platinum-containing double chemotherapy
|
adebeliizumab + platinum-containing double chemotherapy |
|
実験的:group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
実験的:group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
アクティブコンパレータ:group B1-3 almonertinib
|
almonertinib |
|
実験的:group B2-1 SHR-A2009 combined with almonertinib
|
SHR-A2009 combined with almonertinib |
|
アクティブコンパレータ:group B2-2 almonertinib monotherapy
|
almonertinib monotherapy |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Part A1 : pCR rate;
時間枠:about 24 months
|
about 24 months
|
|
Part A2 : 2-year DFS rate;
時間枠:about 24 months
|
about 24 months
|
|
Part A3 : pCR rate and 18-month EFS rate;
時間枠:about 18 months
|
about 18 months
|
|
Part B1 : 2-year DFS rate.
時間枠:about 24 months
|
about 24 months
|
|
Part B2 : MPR rate.
時間枠:about 24 months
|
about 24 months
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
The incidence and grade of adverse events;
時間枠:about 48 months
|
about 48 months
|
|
surgical complications;
時間枠:about 24 months
|
about 24 months
|
|
EFS
時間枠:about 24 months ;
|
about 24 months ;
|
|
ORR;
時間枠:about 24 months
|
about 24 months
|
|
DFS and DFS rates;
時間枠:about 24 months
|
about 24 months
|
|
OS ;
時間枠:about 48 months
|
about 48 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- SHR-A2009-203
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。